glepaglutide

News

Ironwood crashes down as FDA seeks new phase 3 trial

Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.

News

Ironwood felled by mixed data in short bowel syndrome trial

Ironwood Pharma has issued an upbeat assessment of phase 3 trial data with apraglutide for short bowel syndrome (SBS), but missed secondary outcome measures led to a sharp

News

Positive phase 3 results for Zealand Pharma's glepaglutide

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the

Ironwood crashes down as FDA seeks new phase 3 trial

Ironwood felled by mixed data in short bowel syndrome trial

Positive phase 3 results for Zealand Pharma's glepaglutide

UK's Mission divests kidney drug to Dimerix for $292m

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks